Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as ...

Discover the key differences between Data Science, Data Engineering, and AI. Learn about their unique roles, technical ...

New data from a phase 1b/2 clinical trial shows that a specific protein called CD47 can help predict how well the investigational drug evorpacept works for patients with metastatic breast cancer, ALX ...

Supervised learning algorithms like Random Forests, XGBoost, and LSTMs dominate crypto trading by predicting price directions ...

Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – ...

Active attacks exploit Metro4Shell (CVE-2025-11953) in React Native CLI to execute commands and deploy Rust malware.

Generative AI (GenAI) has moved rapidly from experimentation into day-to-day use across many organizations. Over the past ...

People familiar with the rollout say Kepler is not a consumer product and is restricted to internal use, aimed at reducing ...

Researchers at the Department of Energy's Oak Ridge National Laboratory are breathing new life into the scientific ...

Viking Therapeutics has provided a series of updates this January concerning its clinical development pipeline, with a primary focus on its obesity treatment ca ...

EGFR drug ALX2004 and evorpacept, which recently showed activity with Jazz's Ziihera in CD47- and HER2-positive breast cancer.

The Phase Ib/II trial assessed evorpacept plus zanidatamab in previously treated, metastatic HER2-expressing cancers.